Controlled Substance Market Report 2026

The controlled substance market size has grown strongly in recent years. It will grow from $100.19 billion in 2025 to $107.29 billion in 2026 at a compound annual growth rate (CAGR) of 7.1%. The growth in the historic period can be attributed to stringent government regulations, rise in chronic diseases, increasing opioid prescriptions, advancements in drug formulation, limited awareness of drug misuse.

The controlled substance market size is expected to see strong growth in the next few years. It will grow to $145.9 billion in 2030 at a compound annual growth rate (CAGR) of 8%. The growth in the forecast period can be attributed to growing adoption of digital monitoring tools, expansion of online pharmacies, rise in telemedicine, increasing investment in precision medicine, development of non-addictive alternatives. Major trends in the forecast period include increasing prescription drug abuse monitoring, growth of telepharmacy and online dispensing, rise in personalized medication plans, expansion of controlled substance regulations, adoption of smart drug tracking systems.

The rising prevalence of chronic diseases is expected to drive the growth of the controlled substance market going forward. Chronic diseases are conditions that persist for three months or longer and may worsen over time. Controlled substances are used to manage and treat symptoms associated with chronic conditions, including pain management, neuropsychiatric disorders, autoimmune diseases, cardiovascular diseases, and inflammatory disorders. For instance, in January 2023, according to the National Library of Medicine, a US-based agency, the number of people in the US aged 50 and older with at least one chronic condition is projected to increase by 99.5%, reaching 142.66 million by 2050. Therefore, the increasing prevalence of chronic diseases is driving the growth of the controlled substance market.

Major companies operating in the controlled substance market are introducing technologically advanced solutions, such as precursor legislation frameworks and domestic control systems, to improve regulatory compliance and strengthen monitoring capabilities. Precursor legislation and domestic controls encompass a comprehensive set of national laws, regulations, and surveillance measures that regulate the production, distribution, use, and tracking of precursor chemicals within a country to prevent their diversion into illicit drug manufacturing. For example, in May 2024, the International Narcotics Control Board (INCB), an Austria-based independent treaty body, launched two new digital tools to assist authorities in preventing the diversion of controlled precursors and related chemicals. One tool provides an expanded list of chemical analogues associated with internationally controlled precursors, enabling regulators to identify substitute substances commonly used to bypass existing controls. The second tool delivers an advanced compendium of national drug precursor legislation and domestic control measures, allowing competent authorities to compare regulatory frameworks across countries and evaluate risks linked to cross-border chemical movements. These developments demonstrate the market’s transition toward digitalized, data-driven control systems, building on earlier innovations such as the INCB’s e-module, and emphasize the growing role of technology in protecting the legal supply chain of controlled substances.

In November 2023, Noramco, a US-based pharmaceutical manufacturing company, acquired Halo Pharmaceuticals for an undisclosed amount. Through this acquisition, Noramco seeks to broaden its service portfolio by incorporating drug product formulation development, manufacturing, and packaging capabilities for its active pharmaceutical ingredient (API) customers. Halo Pharmaceuticals is a US-based pharmaceutical manufacturing company that specializes in providing controlled substances.

Major companies operating in the controlled substance market are Merck & Co. Inc., Johnson and Johnson Services Inc., GW Pharmaceuticals plc, Alkermes plc, Sun Pharmaceutical Ltd., F. Hoffmann-La Roche Ltd., AbbVie Inc., Pfizer Inc., Novartis AG, GlaxoSmithKline plc, Sanofi S.A., Bristol-Myers Squibb, Eli Lilly and Company, AstraZeneca, Teva Pharmaceutical Industries, Viatris Inc., Boehringer Ingelheim, Gilead Sciences, Amgen, Regeneron Pharmaceuticals, Abbott Laboratories, Mallinckrodt Pharmaceuticals, Endo International, Indivior plc, Ipsen SA, Cambrex Corporation, Catalent, Lonza Group, Orbis Biosciences Inc., Corium Inc.

North America was the largest region in the controlled substance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the controlled substance market report during the forecast period. The regions covered in the controlled substance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the controlled substance market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the controlled substance market by increasing import costs of raw materials and active pharmaceutical ingredients, impacting production expenses and pricing. Hospital pharmacies and online pharmacies in regions like North America and Europe are most affected due to high import dependency. While cost pressures have slowed some market expansion, tariffs have also encouraged local production and innovation in alternative formulations, fostering opportunities for domestic manufacturers and reducing reliance on foreign suppliers.

The controlled substance market research report is one of a series of new reports that provides controlled substance market statistics, including controlled substance industry global market size, regional shares, competitors with a controlled substance market share, detailed controlled substance market segments, market trends and opportunities, and any further data you may need to thrive in the controlled substance industry. This controlled substance market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

A controlled substance is a drug or chemical, including both illicit drugs and legally prescribed medications, whose manufacture, possession, and use are regulated by the government. Controlled substance medications can cause physical and psychological dependence, and regulatory controls are determined by their potential for abuse or dependency. Despite these risks, such substances can help alleviate pain and manage other symptoms, thereby improving an individual’s quality of life.

The primary categories of controlled substances include opioids, stimulants, depressants, and cannabinoids. Opioids are a class of drugs commonly used to manage moderate to severe pain and may be synthetically produced or derived from the opium poppy plant. These substances are distributed through hospital pharmacies, retail pharmacies, and online pharmacies, and are used across various applications such as pain management, sleep disorders, depression and anxiety, seizures, attention deficit hyperactivity disorder (ADHD), and other conditions.

The controlled substance market consists of sales of morphine, valium, ritalin, heroin, cannabis, diazepam, flunitrazepam, and ketamine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.